Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer

BACKGROUND: First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea as side effects. AXEPT, an Asian phase III study, show...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Cancer
Главные авторы: Miyo, Masaaki, Kato, Takeshi, Yoshino, Takayuki, Yamanaka, Takeharu, Bando, Hideaki, Satake, Hironaga, Yamazaki, Kentaro, Taniguchi, Hiroya, Oki, Eiji, Kotaka, Masahito, Oba, Koji, Miyata, Yoshinori, Muro, Kei, Komatsu, Yoshito, Baba, Hideo, Tsuji, Akihito
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2020
Предметы:
Study Protocol
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7376863/
https://ncbi.nlm.nih.gov/pubmed/32703200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07186-5
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы